We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Bedard, P., Parkes, J. D. & Marsden, C. D. (1977) Nomifensine in Parkinson's disease. British Journal of Clinical Pharmacology, 4, 187–90.CrossRefGoogle Scholar
Capstick, N. & Pudney, H. (1976) A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy. Journal of International Medical Research, 4, 435–40.Google Scholar
Hanks, G. W. & Park, D. M. (1981) Nomifensine. In Research Progress in Parkinson's Disease (fids. Clifford Rose, F. and Capildeo, R.). Pp 345–50. Tunbridge Wells: Pitman MedicalGoogle Scholar
Johnson, D. A. W. (1981) Studies of depressive symptoms in schizophrenia. III. A double blind trial of orphenadrine against placebo. British Journal of Psychiatry, 139, 96–7.Google Scholar
Onuaguluchi, G. (1963) Assessment of drug therapy in parkinsonism. British Medical Journal, i, 443–48.Google Scholar
Park, D. M., Findley, L. J., Hanks, G. & Sandler, M. (1981) Nomifensine: effect in parkinsonian patients not receiving levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 44, 352–4.CrossRefGoogle Scholar
Teychenne, P. F., Park, D. M., Findley, L. J., Rose, F. C. & Calne, D. B. (1976) Nomifensine in parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 39, 1219–21.CrossRefGoogle ScholarPubMed
eLetters
No eLetters have been published for this article.